2022 World Conference on Lung Cancer (ePosters)-EP08.02-143. Shortening of the Turn around time (TAT) in the Examination of Rapid On-Site cytologic Evaluation (ROSE) at transbronchial biopsy.

EP08.02-143. Shortening of the Turn around time (TAT) in the Examination of Rapid On-Site cytologic Evaluation (ROSE) at transbronchial biopsy.

Back to course

Pdf Summary

Summary: This document discusses the potential benefits of Rapid On-Site Cytologic Evaluation (ROSE) in diagnosing lung cancer and implementing Next-Generation Sequencing (NGS) testing. The study found that ROSE can improve the diagnosis rate of lung cancer and reduce the need for additional tests. Furthermore, the success rate of NGS testing was higher in the ROSE group, suggesting that ROSE may facilitate the rapid start of treatment. However, further research is needed to determine the usefulness of ROSE in NGS testing. The study acknowledges its limitations, including being a single institutional and retrospective analysis with a small sample size. Nonetheless, the findings suggest that ROSE has the potential to enhance the diagnostic process for lung cancer.

Asset Subtitle

Yoshihiro Taguchi

Meta Tag

Speaker Yoshihiro Taguchi

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Rapid On-Site Cytologic Evaluation

ROSE

lung cancer diagnosis

Next-Generation Sequencing

NGS testing

diagnostic benefits

reducing additional tests

success rate of NGS testing

facilitating rapid treatment start

limitations of single institutional analysis